Seaport Therapeutics ended Q3 with just north of $403 million, providing runway into 2029 ahead of a Glyph Allo top-line readout in the first half of 2027 and a Glyph-Ago Phase 2A readout in early 2028.
SPTX · Seaport Therapeutics, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Seaport Therapeutics reported a $114.4 million nine-month net loss and $403.8 million in cash, cash equivalents and investments, which management believes will fund operations into 2029 after its IPO.
Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, versus $22.5 million a year earlier. Cash, cash equivalents and investments totaled $403.8 million at September 30, 2026, expected to fund operations into 2029.